Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial.
Snyder EL, Sekela ME, Welsby IJ, Toyoda Y, Alsammak M, Sodha NR, Beaver TM, Pelletier JPR, Gorham JD, McNeil JS, Sniecinski RM, Pearl RG, Nuttall GA, Sarode R, Reece TB, Kaplan A, Davenport RD, Ipe TS, Benharash P, Lopez-Plaza I, Gammon RR, Sadler P, Pitman JP, Liu K, Bentow S, Corash L, Mufti N, Varrone J, Benjamin RJ; for the ReCePI study group.
Snyder EL, et al.
Trials. 2023 Dec 11;24(1):799. doi: 10.1186/s13063-023-07831-x.
Trials. 2023.
PMID: 38082326
Free PMC article.
Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious agents and leukocytes in RBC concentrates. ...Eligible subjects will be randomized up to 7 days before surgery to receive either leu …
Amustaline (S-303)/glutathione (GSH) treatment pathogen reduction technology is designed to inactivate a broad spectrum of infectious …